A Phase 3, Open-Label, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (Ace-536) Versus Epoetin Alfa For The Treatment Of Anemia Due To Ipss-R Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes (Mds) In Esa NaïveSubjects Who Require Red Blood Cell Transfusions (The“Commands”Trial)

NMA HREC Reference Number: HREC/18/CALHN/366 (ERM Project ID: 48824)
NMA SSA Reference Number: SSA/48824/MonH-2018-157652(v1)
Monash Health Ref: RES-18-0000-720X